We’re pleased to share that the HELIOS-B study (A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy), recently published in The Journal of the American College of Cardiology, included the use of Us2.ai’s software to assist with echocardiographic analysis in patients with transthyretin-mediated (ATTR) amyloidosis.
In this large multicenter clinical trial, Us2.ai’s software supported echocardiographic measurements based on American Society of Echocardiography (ASE) guidelines. All AI-generated outputs were carefully reviewed by expert readers, ensuring accuracy.
We’re proud to have contributed tools that helped streamline measurement workflows and enable standardized analysis across sites, advancing high-quality cardiac imaging in the field of cardiology.
